Status:
RECRUITING
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Lead Sponsor:
West China Hospital
Conditions:
Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma
Eligibility:
All Genders
Up to 18 years
Phase:
PHASE2
Brief Summary
The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma ...
Detailed Description
Kaposiform hemangioendothelioma (KHE) and tufted angiomas (TA) are rare vascular tumors, which are apparent predominantly in infancy or early childhood. Currently, no standard treatment regimens exist...
Eligibility Criteria
Inclusion
- Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
Exclusion
- Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 28 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04056962
Start Date
September 1 2019
End Date
October 28 2024
Last Update
May 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610041